

Ref. No: 1589
Date: 04/03/25
Subject: Treatment of breast cancer

REQUEST & RESPONSE

I am conducting analysis on the treatment of breast cancer in secondary care and kindly request your help.

I would be grateful if you could answer the questions below in relation to the number of patients treated with specific medicines between the start of October 2024 to the end of December 2024, or the latest three-month period for which data is available. Please include data for all hospitals in the Trust.

BREAST CANCER

Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of October 2024 to the end of December 2024, or latest 3-month period available?

Name of medicine	Number patients treated
1.1 Abemaciclib (Verzenios)	
1.2 Alpelisib (Piqray)	
1.3 Elacestrant (Orserdu)	
1.4 Fulvestrant (fulvestrant or Faslodex)	
1.5 Inavolisib (Inaqovi)	
1.6 Palbociclib (Ibrance)	
1.7 Ribociclib (Kisqali)	
1.8 Capivasertib (Truqap)	
1.9 Talazoparib (Talzenna)	
1.10 Olaparib (Lynparza)	

Q2. How many patients received the following medicines for **early breast cancer** in the 3 months between the start of October 2024 to the end of December 2024, or latest 3-month period for which data are available?

Name of combination or monotherapy	Number patients treated
2.1 Abemaciclib (Verzenios)	
2.2 Ribociclib (Kisqali)	
2.3 Olaparib (Lynparza)	

Q3. How many patients received the following medicines with **curative** treatment intent in the 3 months between the start of October 2024 to the end of December 2024, or latest 3-month period for which data are available?

Name of combination or monotherapy	Number patients treated
3.1 Abemaciclib (Verzenios)	
3.2 Ribociclib (Kisqali)	

Q4. How many patients were treated with the following medicines in combination with fulvestrant in the 3 months between the start of October 2024 to the end of December 2024, or latest 3-month period available?

Name of combination or monotherapy	Number patients treated
4.1 Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex)	
4.2 Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex)	
4.3 Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex)	

Q5. How many patients were treated with Olaparib (Lynparza) for the following types of breast cancer in the 3 months between the start of October 2024 to the end of December 2024?

Type of breast cancer	Number patients treated
5.1 All types of breast cancer	
5.2 Locally advanced or metastatic breast cancer	

<5

Due to the low number of patients which is less than five for the period, the Trust is withholding the actual number under section 40 – Personal

Information of the Freedom of Information Act due to likelihood of identification of the individual(s).

If the requestor or any other member of the general public can, on the balance of probabilities, identify individuals by cross-referencing the anonymised data with other information that was available to them, then the information is personal data and exempt from disclosure under the Act.